Hypoglossal nerve stimulation implants are approved to treat obstructive sleep apnea in patients who can't tolerate CPAP. A new study published in JAMA Otolaryngology–Head & Neck Surgery suggests the devices may be doing more than keeping the airway open overnight — they may be protecting patients from two of the most common downstream consequences of untreated apnea: diabetes and high blood pressure.
A Two-Year Delay Before the Benefit Appears
Researchers analyzed the Merative MarketScan Commercial Database, identifying 3,786 adults who received a hypoglossal nerve stimulation (HGNS) implant between 2015 and 2024. They matched these patients to 3,395 controls who had obstructive sleep apnea, met the clinical criteria to be HGNS candidates, but did not receive the implant — largely because they were nonadherent to positive airway pressure (PAP) therapy.
The finding that stands out is the timing. In the first two years after implantation, HGNS patients showed no reduction in diabetes risk and actually a higher hazard of a new hypertension diagnosis compared with controls. It was only after crossing the two-year mark that the pattern reversed sharply:
- 81% lower hazard of a new diabetes diagnosis compared with non-implanted controls
- 51% lower hazard of a new hypertension diagnosis, reversing the early-period trend entirely
The researchers describe this as the first study to rigorously demonstrate an association between HGNS and the prevention of both hypertension and diabetes — two conditions that obstructive sleep apnea is known to worsen through repeated overnight drops in blood oxygen and the chronic stress response they trigger.
Why the Delay Matters
The two-year lag is itself a finding, not just a footnote. Sleep apnea's metabolic and cardiovascular damage accumulates gradually, through years of intermittent hypoxia, sympathetic nervous system activation, and disrupted glucose regulation. If HGNS therapy interrupts that process, the study suggests the body doesn't immediately reverse course — it may take a sustained period of consistent, effective airway support before measurable metabolic benefits emerge.
That has a practical implication for how the therapy gets evaluated. Most implant studies, including many of the pivotal trials that led to FDA approval of devices like Inspire and, more recently, LivaNova's aura6000, report outcomes over 12 months. A therapy that shows no metabolic benefit — or even an apparent early cost — at the one-year mark could look unimpressive in a study that stops there, even though the real payoff shows up later.
What the Study Can't Yet Show
The authors note an important limitation: the follow-up period was too short to determine whether HGNS reduces harder cardiovascular endpoints, including arrhythmias, coronary artery disease, or heart failure. The current results establish an association with two metabolic conditions, not a demonstrated reduction in heart attacks or strokes. Because the study is retrospective and observational, it also cannot rule out that patients who stick with an implant for more than two years differ in other health behaviors from those who don't — a form of selection that a randomized trial would be needed to fully exclude.
Still, the size of the effect and the specificity of the two-year threshold make this one of the more detailed looks yet at what happens metabolically once a sleep apnea implant has had time to work.
What This Means for Patients
For patients considering HGNS after failing CPAP, this study adds a new dimension to the decision: the metabolic benefits may not be immediate. Someone expecting a fast improvement in blood pressure or blood sugar within the first year may not see one — and clinicians should set that expectation up front rather than let an early lack of change read as treatment failure. The data instead suggest a longer view is warranted, with diabetes and hypertension risk potentially dropping substantially for patients who continue using the device past the two-year mark. Patients with sleep apnea and either prediabetes or borderline blood pressure may want to discuss with their sleep physician whether sustained HGNS use factors into their broader metabolic risk management, alongside standard measures like weight management and glucose monitoring.
